HRK Adriamycin Raw Materials Powder on sale

CAS:23214-92-8

MF:C27H29NO11

MW:543.53

EINECS:245-495-6

Specification​: 99% min Adriamycin Powder

Sample:Adriamycin Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Adriamycin Usage and Function.

It is clinically used in the treatment of acute and chronic lymphocytic leukemia and solid tumor leukemia, lymphoma, breast cancer, ovarian cancer, soft tissue sarcoma, osteoblastoma, rhabdomyosarcoma, Ewing's sarcoma, nephroblastoma, neuroblastoma, gastric cancer, pancreatic cancer, liver cancer, prostate cancer, head and neck squamous carcinoma, testicular cancer, lung cancer, bladder cancer, medullary thyroid cancer and sarcoma. The toxicity of this product is bone marrow suppression, gastrointestinal reaction and cardiac toxicity.

Uses of Adriamycin.

It is used in the treatment of acute and chronic lymphocytic leukemia and solid tumor. The side effects of this product include myelosuppression myocardial toxicity.

Pharmacological action of Adriamycin

The retention time of doxorubicin in the body was prolonged, and the clearance curve was multiphase, with three phases T1/2 of 0.5 hours, 3 hours and 40 ~ 50 hours, respectively. Clinical mainly used for acute or chronic leukemia, Hodgkin and non-Hodgkin lymphoma, malignant lymphoma, daunorubicin-resistant patients are still sensitive to doxorubicin, Ewing tumor, osteosarcoma, soft tissue tumor, lung cancer, chorionic epithelial cancer, breast cancer, bladder cancer, thyroid cancer and soft tissue tumors also have a certain effect. Combined with cytarabine, vincristine and fluorouracil can increase its curative effect. Tumor cells can become resistant to doxorubicin. Compared with sensitive cells, the permeability of cell membrane decreased, and the uptake of adriamycin decreased and adriamycin was actively excreted. Cells resistant to daunorubicin were cross-resistant to doxorubicin.

Product Method of Bulk Adriamycin Powder.